Takeda Announces Julie Kim as Next CEO, Succeeding Christophe Weber in 2026

Takeda has officially named Julie Kim as its next Chief Executive Officer, set to take over the role in June 2026. Currently serving as the president of Takeda’s U.S. Business Unit, Kim has played a pivotal role in driving the company’s growth and expanding its global presence. The board’s unanimous decision reflects confidence in her leadership, strategic vision, and ability to steer Takeda through the evolving pharmaceutical landscape. Christophe Weber, who has led the company since 2015, will retire after over a decade of impactful leadership, positioning Takeda as a key player in the industry.

With Kim’s appointment, Takeda is preparing for a seamless transition while maintaining its commitment to innovation and patient-centric solutions. Under her leadership, the company is expected to continue its focus on cutting-edge therapies and global expansion. "I’m honored to be entrusted with this role and look forward to building on our strong foundation," Kim said in a statement. As Takeda embarks on this new chapter, industry experts are eager to see how her leadership will shape the company's next phase of growth and scientific advancement.